For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.
He first came into contact with the stock market and shares during his banking apprenticeship. After completing this in 2000, he gained his first journalistic experience in the editorial department of a financial portal. During his subsequent studies in business administration, he also worked in the area of investor relations.
Since then, he has remained true to the capital markets and is excited to report on every newly discovered interesting story - as well as on long-standing success stories.
Commented by Fabian Lorenz
Commented by Fabian Lorenz on July 27th, 2022 | 11:45 CEST
Opportunity for BYD, Plug Power and dynaCERT? Russia turns on the gas tap
Since yesterday, significantly less gas is flowing through the Nord Stream 1 pipeline to Germany. Russia is thus currently supplying only 20% of the possible capacity, showing again how unreliable Russia is and how dependent Western Europe - especially Germany is. On the other hand, it shows how important it is to promote alternative energies and energy efficiency, which means opportunities for companies like BYD, Plug Power and dynaCERT. Chinese carmaker BYD wants to expand its battery production and analysts see over 100% share price potential. dynaCERT could be due for a revaluation due to certification. Plug Power shareholders are currently watching the discussion about the government subsidy for hydrogen in the USA with bated breath.
Read
Commented by Fabian Lorenz on July 21st, 2022 | 11:34 CEST
Buy now? BioNTech, Nordex and MAS Gold
The mood on the world's stock markets has stabilized in recent days. Hopes are alive that inflation and the US dollar have seen their highs for now. Even a soft landing of the US economy is no longer ruled out. Therefore, for example, JPMorgan and Goldman Sachs advise buying shares because, from the perspective of the US banks, the chances of a V-shaped recovery of the stock markets are increasing. That could benefit stocks that have fallen by the wayside in recent months, including BioNTech. The Wiesbaden-based Company could be in for an exciting fall. A weaker US dollar would give a boost to the gold price. Gold explorer MAS Gold should be able to profit from this. Nordex has at least full coffers after two capital increases but continues to have problems. However, Jefferies advises buying.
Read
Commented by Fabian Lorenz on July 20th, 2022 | 13:18 CEST
Nel with a liberation blow - When will Varta and Almonty Industries take off?
Nel has long been one of the hopefuls in the hydrogen sector. But recently, Plug Power had somewhat outstripped the Norwegians. The reason: a lack of major orders at Nel to justify its billion-euro valuation. The major order has now finally arrived, and the stock is stepping on the gas. Since Monday, it has already gained more than 10%, and analysts see further room for improvement. It should also boost other shares along the renewable energy value chain: For example, battery manufacturer Varta and raw material producer Almonty Industries. Almonty, which is actually on its way to becoming the largest tungsten producer outside China, has published convincing estimates for a molybdenum project. With Varta, on the other hand, caution is the order of the day. The chart is battered and another insider sale adds to the uncertainty.
Read
Commented by Fabian Lorenz on July 14th, 2022 | 12:35 CEST
Nel successful in Australia, Rheinmetall recommended by Goldman and Barsele Minerals for the gold comeback
Interest rate fears, a looming recession and war in Ukraine - There are numerous reasons for nervousness on the stock market. But especially in uncertain times, the chances of long-term price gains are high. But where is the safe haven at the moment? Gold, renewable energies or even armaments? Gold is undoubtedly one of the disappointments of the year. The strong US dollar is weighing on the sector. But gold stocks are cheap. Alongside heavyweights, there are also explorers such as Barsele Minerals, and the Canadians bring takeover fantasy. Golden times are predicted for companies in the renewable energy sector. Hydrogen specialist Nel shines with an order from Australia. And defense companies like Rheinmetall are facing a super cycle. At the same time, the MDAX group is also getting involved in fuel cells, and Goldman Sachs advises buying.
Read
Commented by Fabian Lorenz on July 13th, 2022 | 14:27 CEST
MorphoSys facing a takeover? Exciting autumn ahead for BioNTech and XPhyto
Biotech investors could be in for an exciting autumn. After some sharp price corrections, positive things are happening again in the biotech sector. For one thing, the takeover carousel. It all started in June when Pfizer announced the acquisition of migraine specialist Biohaven for USD 11.6 billion, and GlaxoSmithKline plans to swallow Sierra Oncology for around USD 1.9 billion. Recent deals include the acquisitions of ViaCyte, La Jolla Pharmaceutical and Pliant Therapeutics. MorphoSys is also a possible takeover candidate. It could be a win-win for the German biotech company if the price is attractive. Xphyto could also see at least one investment, as a market-ready product has great potential.
Read
Commented by Fabian Lorenz on July 7th, 2022 | 14:33 CEST
A big surprise at BioNTech, and what are Valneva and NervGen doing?
Surprise at BioNTech: competitor CureVac sues the Mainz-based biotech company for alleged patent infringements. Specifically, the lawsuit concerns BioNTech's Corona vaccine, which is based on mRNA technology. CureVac founder Ingmar Hoerr, in turn, is considered the discoverer of this new vaccination technology. However, CureVac failed with the development of its own Corona vaccine. Valneva also had no luck with its Corona vaccine, but it seems to have an attractive product pipeline. Nevertheless, the euphoria over the entry of the US pharmaceutical group Pfizer has faded. The situation at NervGen is different: according to experts, NervGen could achieve its greatest success in decades with NVG-291 in the fight against Alzheimer's disease. Tomorrow, a capital increase is to be completed, and the share price will likely regain momentum.
Read
Commented by Fabian Lorenz on June 30th, 2022 | 12:44 CEST
BYD on board with Apple? Rebound at Nordex and Defense Metals?
The end of the combustion engine is the next driver of electromobility and thus also of renewable energies. After all, the electricity for e-cars has to come from somewhere. The EU has agreed to ban the sale of diesel and gasoline-powered cars from 2035. That should give further impetus to carmakers like BYD. This is just one of the many good news stories from the Chinese group. In the future, it is reportedly known that it will supply Apple. But from a chart perspective, investors need to pay attention. Nordex also has to be careful not to miss the boat with the competition. To this end, the wind turbine manufacturer has raised fresh capital. Both electromobility and wind and solar technology need selenium earths. And Defense Metals is benefiting from this.
Read
Commented by Fabian Lorenz on June 29th, 2022 | 12:18 CEST
Buy or sell? Nel, Zalando, Aspermont under analyst review
After the heavy losses of the past months, a countermovement seems to be starting at the moment. Whether this will turn into a real summer rally remains to be seen. Buy or sell is the question. Analysts see a price potential of over 50% for Nel ASA. Even though competition from China and India is increasing. Aspermont also appears attractive at the current price level. The latest quarterly figures were positive, and the positioning of the small-cap in the booming commodities sector is promising. At Zalando, analysts react to the profit warning, and the price targets are significantly reduced. Nevertheless, some advise buying the online fashion retailer, but not everyone.
Read
Commented by Fabian Lorenz on June 23rd, 2022 | 11:35 CEST
Takeover fantasy: +50% in Valneva shares, and what are BioNTech and Defence Therapeutics doing?
Tension is rising in the biotech sector as the takeover merry-go-round spins faster and has now hit Valneva. Pfizer's entry caused the stock to explode 50% in three trading days. Earlier, Pfizer had announced it would acquire migraine specialist Biohaven for USD 11.6 billion. Other pharmaceutical giants are also active: Halozyme wants to swallow Antares Pharma, a specialist in urology and endocrinology, for USD 960 million. The acquisition of Sierra Oncology is costing GlaxoSmithKline around USD 1.9 billion. Like Valneva, Defence Therapeutics is about to start important trials and could attract a major partner. A takeover of BioNTech is unlikely, but the flagship German biotech should also benefit from improved sentiment in the industry. The coming week should be operationally exciting for shareholders.
Read
Commented by Fabian Lorenz on June 22nd, 2022 | 14:39 CEST
Golden times for Nel and Varta? Tension is rising at First Hydrogen
The prices for oil, gas & Co. remain at a high level this week, not least because Russia has reduced gas supplies to Europe. In Germany, Economics Minister Robert Habeck is working at full speed on emergency plans for the winter and is calling for energy savings. In the long term, there will be no way around renewable energies. Analysts expect golden times for companies like Nel ASA and Varta. But smaller innovative companies like hydrogen pure-play First Hydrogen are also interesting. That is because analysts expect demand for hydrogen to outstrip supply massively. In the battery sector, Goldman Sachs recommends buying the Varta share. The MDAX group's sales are expected to more than double in the coming years, thanks to electromobility. The annual general meeting was held yesterday.
Read